Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans.

2 Dec 2009

NuGEN Technologies launches its next generation Ovation RNA-Seq System

NuGEN Technologies, Inc., a pace-setter in genomic sample preparation, enters the next generation sequencing (NGS) market today with its Ovation RNA-Seq System, a revolutionary method of sample preparation that broadens research horizons with a more comprehensive representation of the transcriptome created from samples of a few hundred picograms.

2 Dec 2009

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, today announced the results of a study demonstrating for the first time the capability to detect and automatically measure key activity indicators of cancer cell signal transduction pathways in intact tissue.

2 Dec 2009

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

30 Nov 2009

Study reveals that ghrelin can increase resistance to Parkinson's disease

Ghrelin, a hormone produced in the stomach, may be used to boost resistance to, or slow, the development of Parkinson's disease, Yale School of Medicine researchers report in a study published in a recent issue of the Journal of Neuroscience.

25 Nov 2009

Faulty enzyme may contribute to malignant brain tumour formation

Around 70 per cent of people with a type of brain tumour - called a low-grade glioma - have a faulty version of an enzyme called IDH1. The mutation is also found in a significant proportion of patients with acute myeloid leukaemia.

25 Nov 2009

Ocimum Biosolutions' Biotracker awarded caBIG Bronze Compatibility Certification

Ocimum Biosolutions today announced that its specialty life science Laboratory Information Management System (LIMS), Biotracker™ has been awarded the prestigious caBIG® (cancer Biomedical Informatics Grid®) Bronze Compatibility Certification by the National Cancer Institute, an institute of the National Institutes of Health, U.S. Department of Health and Human Services.

24 Nov 2009

Study reveals high levels of cardiac biomarkers in the blood of heart attack patients

Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study.

24 Nov 2009

Mutated IDH1 gene linked to the progression of gliomas

23 Nov 2009

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough discovery shows that the mutated form of IDH1 produces a metabolite, 2-hydroxyglutarate (2HG), which may contribute to the formation and malignant progression of gliomas, the most common type of brain cancers.

23 Nov 2009

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

Lexicon Pharmaceuticals, Inc., announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders."

23 Nov 2009

WaferGen Biosystems launches new SmartChip Service for gene-expression profiling of thousands of genes

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genetic analysis systems, today announced a new, innovative service for gene-expression profiling of thousands of genes using the SmartChip(TM) Real-Time PCR System. By taking advantage of the SmartChip Real-Time PCR system, WaferGen will offer universities, pharmaceutical and diagnostic companies a service that utilizes pathway-specific gene panels to discover and validate new biomarkers.

19 Nov 2009

VisEn Medical launches two new agents for imaging quantification

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

19 Nov 2009

Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010.

19 Nov 2009

RBM and Covance sign biomarker alliance and services agreement

Rules-Based Medicine, Inc. (RBM) today announced it has entered into a biomarker alliance and services agreement with Covance Inc. that will provide biotechnology and pharmaceutical companies with a powerful combination of biomarker technologies and services for use in drug development. Under terms of the agreement, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and RBM shall use Covance as its exclusive referral source for laboratory testing services.

19 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Covance and Rules-Based Medicine enter into biomarker alliance and services agreement

Covance Inc., a leading provider of drug development services, announced today that it entered into a biomarker alliance and services agreement with Rules-Based Medicine, Inc. (RBM), a leading provider of multiplexed protein biomarker testing to the pharmaceutical industry.

19 Nov 2009

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Clinical Data, Inc. today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.

18 Nov 2009

Mayo Clinic licenses non-exclusive rights to Expression Pathology's Liquid Tissue patent

Expression Pathology, a leader in tissue proteomic analysis, today announced Mayo Clinic has licensed non-exclusive rights to Expression Pathology's Liquid Tissue® patent for use in diagnosis of systemic amyloidosis in formalin-fixed tissue.

18 Nov 2009

Biomarker News and Research

Further Reading

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

NuGEN Technologies launches its next generation Ovation RNA-Seq System

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Minerva Biotechnologies grants Clarient exclusive commercializing rights to its MUC1 diagnostic test

Study reveals that ghrelin can increase resistance to Parkinson's disease

Faulty enzyme may contribute to malignant brain tumour formation

Ocimum Biosolutions' Biotracker awarded caBIG Bronze Compatibility Certification

Study reveals high levels of cardiac biomarkers in the blood of heart attack patients

Mutated IDH1 gene linked to the progression of gliomas

Mutated IDH1 gene has novel enzyme activity consistent with cancer-causing gene: Study

Top-line data from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS to be presented

WaferGen Biosystems launches new SmartChip Service for gene-expression profiling of thousands of genes

VisEn Medical launches two new agents for imaging quantification

Altair Therapeutics initiates its IL-4 receptor alpha inhibitor bronchoprovocation phase 2 trial

RBM and Covance sign biomarker alliance and services agreement

New biomarkers can predict patients' response to certain drugs

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Covance and Rules-Based Medicine enter into biomarker alliance and services agreement

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Mayo Clinic licenses non-exclusive rights to Expression Pathology's Liquid Tissue patent

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News